FTC Charges 'Pharma Bro' Shkreli for Violating Industry Ban

Tuesday, 13 October 2026, 17:05

FTC accusations against 'Pharma Bro' Shkreli reveal significant violations of a lifetime industry ban. This post discusses the court's actions against him. The Federal Trade Commission (FTC) has moved to hold Martin Shkreli in contempt for continually breaching his lifetime prohibition from the pharmaceutical sector. In a court filing, the FTC emphasizes the urgency of this action in light of Shkreli's repeated offenses.

Thehill — FTC Charges 'Pharma Bro' Shkreli for Violating Industry Ban

FTC Actions Against Martin Shkreli

The Federal Trade Commission (FTC) has initiated proceedings against Martin Shkreli, known as 'Pharma Bro,' for violating a lifetime ban imposed on him from participating in the pharmaceutical industry. The commission, along with seven states, argues that Shkreli has been flagrantly violating this order, prompting them to seek contempt charges in a U.S. District Court.

Legal Implications

The FTC's court filing highlights serious legal issues.
Shkreli's actions could lead to significant penalties.
This case exemplifies regulatory efforts to enforce industry bans.

Background on Shkreli's Ban

Shkreli's lifetime ban resulted from his fraudulent activities during his tenure at Turing Pharmaceuticals, where he drastically raised the price of a critical medication. The FTC's current actions underline the seriousness of compliance with such bans in the pharmaceutical sector.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.